Treatment of low NCAM expressing WT xenografts (LNWT) with low dose lorvotuzumab-mertansine resulted in attenuation of tumour growth, however without reduction in tumour size, possibly due to incomplete abolition of NCAM+ cells harbouring WT-initiating capacity. This evidence concerns the gene NCAM1 and neoplasm.